Head to Head Analysis: Bionano Genomics (NASDAQ:BNGO) and Codexis (NASDAQ:CDXS)

Codexis (NASDAQ:CDXS – Get Free Report) and Bionano Genomics (NASDAQ:BNGO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Profitability

This table compares Codexis and Bionano Genomics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Codexis -21.77% -45.54% -14.53%
Bionano Genomics -96.87% -85.00% -51.86%

Insider and Institutional Ownership

78.5% of Codexis shares are owned by institutional investors. Comparatively, 11.3% of Bionano Genomics shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Codexis has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.

Earnings & Valuation

This table compares Codexis and Bionano Genomics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Codexis $70.39 million 1.81 -$43.97 million ($0.34) -3.41
Bionano Genomics $28.51 million 0.49 -$26.40 million ($1.97) -0.51

Bionano Genomics has lower revenue, but higher earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Codexis and Bionano Genomics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Codexis 1 1 2 0 2.25
Bionano Genomics 1 0 1 0 2.00

Codexis currently has a consensus price target of $6.50, indicating a potential upside of 460.34%. Bionano Genomics has a consensus price target of $6.00, indicating a potential upside of 500.00%. Given Bionano Genomics’ higher probable upside, analysts plainly believe Bionano Genomics is more favorable than Codexis.

Summary

Codexis beats Bionano Genomics on 11 of the 14 factors compared between the two stocks.

About Codexis

(Get Free Report)

Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.

About Bionano Genomics

(Get Free Report)

Bionano Genomics, Inc. develops genome analysis tools for research and clinical laboratories. Its technology is designed to help analyze large-scale changes in DNA that may be difficult to detect with some conventional methods. The company’s core offering is optical genome mapping (OGM), which labels and images long DNA molecules to identify structural variants and other genomic features. Its Saphyr system, consumables and analysis software support OGM workflows used in areas such as genetic disease and cancer research.

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.